



A REVIEW ON INTEGRATING ARTIFICIAL INTELLIGENCE INTO DRUG DEVELOPMENT: REVOLUTIONIZING THE PHARMACEUTICAL LANDSCAPE

**Oza Vrushant Pranay, Dr. Anuradha P. Prajapati, Mrs. Bhoomi S. Patel,
Dr. Sachin B. Narkhede, Dr. Shailesh Luhar**

Smt B.N.B Swaminarayan Pharmacy College, Salvav-Vapi, India

Article DOI: <https://doi.org/10.36713/epra15249>

DOI No: 10.36713/epra15249

ABSTRACT

AI revolutionizes pharmaceuticals by expediting drug discovery through data analysis, predicting candidates, and enabling medication repurposing. It extends to manufacturing, ensuring quality, reducing waste, and optimizing production. AI enhances supply chain management, predicting demand and preventing shortages. Its continuous learning adapts to evolving data, aligning drug development with the latest advancements. This synergy promises efficient, personalized, and effective pharmaceutical processes, heralding a transformative era for improved patient outcomes and advanced healthcare solutions.

KEY WORDS: *Artificial intelligence (AI), Pharmaceutical industry, Drug development, Continuous learning, Supply chain optimization.*

INTRODUCTION

Artificial intelligence (AI) is increasingly being used in numerous sectors of society, including the pharmaceutical business. In this review, we emphasize the application of artificial intelligence (AI) in several areas of the pharmaceutical business, such as drug research and development, medication repurposing, improving pharmaceutical productivity, and clinical trials, among others; such use decreases the need for human intervention.

Artificial intelligence (AI) is the computer simulation of the human intelligence process. Acquiring knowledge, formulating rules for interpreting the information, reaching approximate or definite conclusions, and self-correction are all part of the process. The advancement of AI can be viewed as a two-edged sword: many fear that it will endanger their jobs; on the other hand, every advancement in AI is applauded because it is believed to substantially contribute to the welfare of society. AI is utilized in a variety of industries, from developing new instructional approaches to automating commercial processes. Adoption of AI in the drug development process has progressed from hype to hope. This review discusses the potential applications of AI in the drug development pipeline in drug development strategies and processes, pharmaceutical R&D efficiency and attrition, and collaborations between AI and pharmaceutical businesses. ⁽¹⁾⁽²⁾

AI in the lifecycle of Pharmaceutical Product


The integration of artificial intelligence (AI) in the pharmaceutical industry has emerged as a transformative force, revolutionizing the entire drug development process from the laboratory to patient care. AI's impact is particularly noteworthy in rational drug design, a critical phase where novel therapeutic agents are conceived.

Moreover, AI plays a pivotal role in decision-making throughout the drug development pipeline. E-VAI, an analytical and decision-making AI platform developed by Eularis, exemplifies this by utilizing ML algorithms and a user-friendly interface. This platform creates analytical roadmaps based on factors such as competitors, key stakeholders, and existing market share. By predicting key drivers in pharmaceutical sales, E-VAI empowers marketing executives to make informed decisions, strategically allocate resources, and optimize market share. This predictive capability is instrumental in reversing poor sales trends and enables executives to anticipate where to make strategic investments. ^(3,4)

Beyond drug development, AI contributes significantly to personalized medicine by assisting in the determination of the right therapy for individual patients. Through the analysis of vast datasets, AI can identify treatment options tailored to a patient's genetic makeup, improving treatment outcomes, and minimizing adverse effects. ⁽⁴⁾

Examples of method domains of AI**1. Artificial intelligence:****(A) Machine learning:**

- I. Artificial neural network
 - (a) Perceptron
 - (b) Recurrent neural network
 - (c) Feed/forward network
 - (d) Botzmann network
 - (e) Convolutional neural network
- II. Decision tree algorithm
 - (a) Random forest
 - (b) Classification and regression tree
- III. Instance based algorithm
 - (a) Self-organizing map
 - (b) K-nearest neighbor
 - (c) Support vector machine

**Figure 1: Examples of Method Domains of AI****Drug Development Process**

The feedback-driven drug development method begins with existing results gathered from a variety of sources, including high-throughput compound and fragment screening, computational modelling, and literature information. In this method, induction and deduction are alternated. This inductive-deductive cycle finally results in hit and lead compounds that are optimized. The automation of specific stages of the drug development cycle lowers randomness and errors while increasing drug development efficiency. De novo design methodologies necessitate organic chemistry understanding for in silico compound synthesis and virtual screening models that serve as surrogates for biochemical and biological efficacy and toxicity studies. Finally, active learning algorithms enable the discovery of new or unique compounds with promising anti-disease activity. ⁽⁵⁾

.A chemical with a reactive functional group and atoms that interact with the active site of a biological target is referred to as a building block. This active site is a specific location within the biological target to which the chemical (or substratum) attaches via interaction forces. The binding of a substrate to an active site can be represented by 'lock and key' or "induced-fit" models. ⁽⁶⁾

R&D Efficiency and Attrition Rate in Drug Development

In the complex landscape of pharmaceutical drug development, the pursuit of innovation is hindered by an alarming decline in research and development (R&D) efficiency. Despite the strict adherence to well-established drug-likeness guidelines, pharmaceutical companies are grappling with substantial challenges, and the ramifications are evident in the diminishing rate of new drugs approved by the FDA per billion dollars spent on R&D.

The cost of bringing a new drug to market has skyrocketed from \$800 million in 2001 to an estimated \$3 billion today. This escalating cost encompasses the entire spectrum of drug development, factoring in the failures that occur at various stages. The average estimate reflects the financial burden required to usher a new drug into the clinical setting. The worrisome trend of declining drug approvals per billion dollars spent on R&D prompted a comprehensive analysis by Scannell et al. The findings distilled the key factors contributing to R&D inefficiency into four categories: the 'better than Beatles problem,' the 'cautious regulator problem,' the 'throw money at it' tendency, and the 'basic-research-brute-force' bias. ⁽⁷⁾

Attrition rates in drug development present another formidable challenge. First-in-human trials conducted by ten established pharmaceutical companies between 1991 and 2000 revealed a success rate of merely 11%. A staggering 62% of new chemical entities in Phase IIb and Phase III clinical trials do not reach the clinic. The predominant causes of attrition in late-stage clinical development include issues related to clinical safety and efficacy, formulation, pharmacokinetics, bioavailability, and toxicity. ⁽⁸⁾⁽⁹⁻¹⁴⁾

Use AI in Drug Discovery

The enormous chemical space, which contains more than 10⁶⁰ compounds, promotes the development of a huge number of pharmacological molecules. However, the lack of new technology constrains the medication development process, making it a time-consuming and costly endeavour that can be addressed by applying AI. AI can identify hit and lead compounds, as well as providing faster validation of the drug target and optimization of drug structure design. ^{(15) (16)} Numerous in silico methods for virtual screening compounds from virtual chemical spaces, as well as structure and ligand-based methodologies, allow better profile analysis, faster elimination of nonlead compounds, and therapeutic molecule selection at a lower cost. ⁽¹⁷⁾




Figure 2: Role of Artificial Intelligence (AI) in Drug Discovery

AI in Drug Screening ⁽¹⁸⁻¹⁹⁾

The process of researching and developing a medicine can take a decade and cost an average of \$2.8 billion. Even still, nine out of ten medicinal molecules fail Phase II clinical studies and are not approved by regulatory authorities. Algorithms like Nearest-Neighbor classifiers, RF, extreme learning machines, SVMs, and deep neural networks (DNNs) are used for VS and can predict in vivo activity and toxicity.

A. Prediction of the Physicochemical Properties

Physicochemical features of the medication, such as solubility, partition coefficient (logP), degree of ionization, and intrinsic permeability, have an indirect effect on its pharmacokinetics and target receptor family and must thus be addressed when creating a new medicine. Physicochemical qualities can be predicted using a variety of AI-based methods.



B. Prediction of Bioactivity

The affinity of drug molecules for the target protein or receptor determines their efficacy. Drug molecules that do not bind with or have affinity for the targeted protein will not be able to provide the therapeutic response.

C. Prediction of Toxicity

To avoid hazardous effects, it is critical to forecast the toxicity of any therapeutic molecule. Cell-based in vitro assays are frequently employed as preliminary investigations, followed by animal experiments to determine a compound's toxicity, raising the cost of drug research. Toxtree, LimTox, pkCSM, admetSAR, and other web-based applications are available to help minimize costs. The different AI tools used in drug discovery are listed in Table 1.

TABLE 1: Different AI tools used in drug discovery

Sr no.	Tools	Details
1	DeepChem	MLP model that uses a python-based AI system to find a suitable candidate in drug discovery
2	DeepTox	Software that predicts the toxicity of total of 12 000 drugs
3	DeepNeuralNetQSAR	Python-based system driven by computational tools that aid detection of the molecular activity of compounds
4	ORGANIC	A molecular generation tool that helps to create molecules with desired properties
5	PotentialNet	Uses NNs to predict binding affinity of ligands

AI in designing drug molecules ⁽²⁰⁻²²⁾

A. Prediction of the target protein structure

It is critical to assign the correct target while creating a pharmacological molecule for successful treatment. Numerous proteins are involved in the disease's development and, in certain situations, are overexpressed.

B. Predicting drug-protein interactions

Drug-protein interactions are critical to the effectiveness of a therapy. Predicting a medication's interaction with a receptor or protein is critical for understanding its efficacy and effectiveness, allowing drug repurposing, and preventing polypharmacology.

AI-based advanced applications ⁽²³⁻²⁸⁾

1. AI-based nanorobots for drug delivery
2. AI in combination drug delivery and synergism/antagonism prediction
3. AI emergence in nanomedicine

Challenges ⁽²⁹⁾

In the realm of AI and machine learning applications within the pharmaceutical industry, significant strides have been made; however, the practical implementation and seamless integration of these technologies into the drug discovery process remain formidable challenges. One primary obstacle lies in the inefficient integration of diverse datasets, encompassing raw data, processed data, metadata, and candidate data. The absence of a standardized method for collecting and collating these datasets impedes efficient analysis, hindering the accuracy of machine learning algorithms. Addressing this issue necessitates the development of more effective methods for integrating diverse data into repositories before embarking on the drug discovery journey.

Future Scope ⁽³⁰⁾

The main potential of AI in the pharmaceutical industry is to reduce costs and increase efficiency. Extensive research has demonstrated that dynamic learning can distinguish profoundly exact AI models while using half or less information than traditional AI and information subsampling approaches. Although the reason for this increased productivity is not fully understood, it appears that reduced repetition and predisposition, as well as gaining more significant information to traverse choice limits, are key components in this improved execution.

1. **Accelerated Drug Discovery:** AI has the potential to significantly expedite the drug discovery phase by predicting and identifying potential drug candidates more efficiently.

2. **Precision Medicine and Personalized Treatment:** AI's ability to analyze large-scale patient data, including genomics, proteomics, and clinical records, facilitates the emergence of personalized medicine.

3. **Optimized Clinical Trials:** AI can streamline and optimize clinical trial processes, from patient recruitment to protocol design and monitoring. Predictive analytics can help identify suitable patient populations, reducing trial costs and timelines.



- 4. Drug Repurposing:** AI algorithms excel in identifying potential alternative uses for existing drugs. By analyzing large-scale biological and clinical datasets, AI can uncover new therapeutic indications for drugs already approved for other conditions.
- 5. AI-Integrated Biomarker Discovery:** Biomarkers play a crucial role in disease diagnosis, prognosis, and treatment response.
- 6. Drug Safety and Toxicity Prediction:** AI models can predict potential safety issues and toxicity early in the drug development process, reducing the risk of adverse effects during clinical trials or post-market.
- 7. AI-Driven Drug Manufacturing and Supply Chain Optimization:** AI can optimize drug manufacturing processes, ensuring quality control, minimizing waste, and enhancing overall efficiency.
- 8. Continuous Learning and Adaptation:** The dynamic nature of AI allows for continuous learning and adaptation based on real-world data.

As the synergy between AI and drug development continues to evolve, the potential for innovation and improvement in patient outcomes becomes increasingly promising.

CONCLUSION

In conclusion, the symbiotic relationship between artificial intelligence (AI) and the pharmaceutical industry heralds a transformative era. AI expedites drug discovery, enabling rapid identification of candidates and repurposing existing medications. Its integration in manufacturing optimizes processes, ensuring quality and efficiency, while in the supply chain, AI predicts demand and prevents shortages. The dynamic learning capability of AI aligns drug development with evolving knowledge, promising innovation, efficiency, and personalized healthcare. As AI technologies advance, the pharmaceutical landscape stands on the cusp of significant improvements, offering a future characterized by cutting-edge solutions and enhanced patient outcomes.

REFERENCES

- Mak, K. K., & Pichika, M. R. (2019). *Artificial intelligence in drug development: present status and future prospects*. *Drug discovery today*, 24(3), 773-780.
- Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021). *Artificial intelligence in drug discovery and development*. *Drug discovery today*, 26(1), 80.
- Mishra, V. (2018). *Artificial intelligence: the beginning of a new era in pharmacy profession*. *Asian Journal of Pharmaceutics (AJP)*, 12(02).
- Duch, W., Swaminathan, K., & Meller, J. (2007). *Artificial intelligence approaches for rational drug design and discovery*. *Current pharmaceutical design*, 13(14), 1497-1508.
- Fleming, N. (2018). *How artificial intelligence is changing drug discovery*. *Nature*, 557(7706), S55-S55.
- Yuan, Y., Pei, J., & Lai, L. (2011). *LigBuilder 2: a practical de novo drug design approach*. *Journal of chemical information and modeling*, 51(5), 1083-1091.
- Zhu, T., Cao, S., Su, P. C., Patel, R., Shah, D., Chokshi, H. B., ... & Hevener, K. E. (2013). *Hit identification and optimization in virtual screening: Practical recommendations based on a critical literature analysis: Miniperspective*. *Journal of medicinal chemistry*, 56(17), 6560-6572.
- Anderson, A. C. (2012). *Structure-based functional design of drugs: from target to lead compound*. *Molecular Profiling: Methods and Protocols*, 359-366.
- Hall, D. R., Ngan, C. H., Zerbe, B. S., Kozakov, D., & Vajda, S. (2012). *Hot spot analysis for driving the development of hits into leads in fragment-based drug discovery*. *Journal of chemical information and modeling*, 52(1), 199-209.
- Alanine, A., Nettekoven, M., Roberts, E., & Thomas, A. W. (2003). *Lead generation-enhancing the success of drug discovery by investing in the hit to lead process*. *Combinatorial chemistry & high throughput screening*, 6(1), 51-66.
- DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2015). *The cost of drug development*. *New England Journal of Medicine*, 372(20), 1972-1972.
- Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). *Diagnosing the decline in pharmaceutical R&D efficiency*. *Nature reviews Drug discovery*, 11(3), 191-200.
- Reddy, A. S., & Zhang, S. (2013). *Polypharmacology: drug discovery for the future*. *Expert review of clinical pharmacology*, 6(1), 41-47.
- Tormay, P. (2015). *Big data in pharmaceutical R&D: creating a sustainable R&D engine*. *Pharmaceutical medicine*, 29(2), 87-92.
- Zang, Q., Mansouri, K., Williams, A. J., Judson, R. S., Allen, D. G., Casey, W. M., & Kleinstreuer, N. C. (2017). *In silico prediction of physicochemical properties of environmental chemicals using molecular fingerprints and machine learning*. *Journal of chemical information and modeling*, 57(1), 36-49.
- Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019). *Concepts of artificial intelligence for computer-assisted drug discovery*. *Chemical reviews*, 119(18), 10520-10594.
- Hessler, G., & Baringhaus, K. H. (2018). *Artificial intelligence in drug design*. *Molecules*, 23(10), 2520.



18. Rupp, M., Körner, R., & Tetko, I. V. (2010). Estimation of acid dissociation constants using graph kernels. *Molecular Informatics*, 29(10), 731-740.
19. Öztürk, H., Özgür, A., & Ozkirimli, E. (2018). DeepDTA: deep drug–target binding affinity prediction. *Bioinformatics*, 34(17), i821-i829.
20. Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., ... & Urban, L. (2012). Large-scale prediction and testing of drug activity on side-effect targets. *Nature*, 486(7403), 361-367.
21. Feng, Q., Dueva, E., Cherkasov, A., & Ester, M. (2018). Padme: A deep learning-based framework for drug-target interaction prediction. *arXiv preprint arXiv:1807.09741*.
22. Karimi, M., Wu, D., Wang, Z., & Shen, Y. (2019). DeepAffinity: interpretable deep learning of compound–protein affinity through unified recurrent and convolutional neural networks. *Bioinformatics*, 35(18), 3329-3338.
23. Hassanzadeh, P., Atyabi, F., & Dinarvand, R. (2019). The significance of artificial intelligence in drug delivery system design. *Advanced drug delivery reviews*, 151, 169-190.
24. Fu, J., & Yan, H. (2012). Controlled drug release by a nanorobot. *Nature biotechnology*, 30(5), 407-408.
25. Calzolari, D., Bruschi, S., Coquin, L., Schofield, J., Feala, J. D., Reed, J. C., ... & Paternostro, G. (2008). Search algorithms as a framework for the optimization of drug combinations. *PLoS computational biology*, 4(12), e1000249.
26. Calzolari, D., Bruschi, S., Coquin, L., Schofield, J., Feala, J. D., Reed, J. C., ... & Paternostro, G. (2008). Search algorithms as a framework for the optimization of drug combinations. *PLoS computational biology*, 4(12), e1000249.
27. Tsigelny, I. F. (2019). Artificial intelligence in drug combination therapy. *Briefings in bioinformatics*, 20(4), 1434-1448.
28. Sacha, G. M., & Varona, P. (2013). Artificial intelligence in nanotechnology. *Nanotechnology*, 24(45), 452002.
29. Henstock, P. V. (2019). Artificial intelligence for pharma: time for internal investment. *Trends in pharmacological sciences*, 40(8), 543-546.
30. Chan, H. S., Shan, H., Dahoun, T., Vogel, H., & Yuan, S. (2019). Advancing drug discovery via artificial intelligence. *Trends in pharmacological sciences*, 40(8), 592-604.